Now available: Mentype® AMLplus for Fast and Comprehensive AML Mutation Profiling

When it comes to Acute Myeloid Leukemia, time is of the essence.

AML can turn lethal within weeks. ELN 2022 guidelines¹ call for key genetic aberrations to be identified within 3–5 days of diagnosis, as classification, prognosis, and therapy planning all depend on a timely molecular picture.

The challenge: the initial profiling must be both comprehensive and fast. Achieving both in a single workflow has remained difficult.

BIOTYPE addresses this with the launch of Mentype^®AMLplus, a multiplex PCR-based kit for the simultaneous detection of key AMLmutation hotspots from a single blood or bone marrow sample.

‍Key features:

• Single multiplex PCR reaction covering five relevant mutation targets:
  IDH1, IDH2, FLT3 (ITD & TKD), NPM1, and CEBPA bZIP
• Compatible with Mentype® AMLplex^QS (CE-IVD) for parallel gene fusion screening within the same analytical run
• Results available in approximately 4 hours after nucleic acid extraction
• Runs on standard PCR and capillary gel electrophoresis platforms
• Includes the integrated AMLplus Profiler for automated, standardized result interpretation

For further information, visit the Mentype^® AMLplus product page or contact us at products@biotype.de.

‍

1. Döhner etal.: Diagnosis and management of AML in adults: 2022 recommendations from aninternational expert panel on behalf of the ELN. Blood (2022) 140 (12):1345–1377. https://doi.org/10.1182/blood.2022016867

Research Use Only. RUO productsmust be validated by the customer with clinically relevant material fordiagnostic purposes.